Table 3.
The features of the studies relating Ki-67/MIB-1 to patients’ prognosis
| Type of survival | First author | Country | Year | Patients | Age | Median FU | Test method | Antibody | Threshold, % | HR (95% CI) | P-value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DFS | Kjellman et al1 | Sweden | 2003 | 30 | 62 | 146 months | IHC | MIB-1 | 1.85 | 4.93 (1.91–12.77) | 0.001 |
| Ito et al12 | Japan | 2010 | 371 | 49 | 125 months | IHC | Anti Ki-67 antibody | 1 | 4.13 (2.19–7.75) | <0.001 | |
| Miyauchi et al22 | Japan | 2013 | 390 | 50.8 | 88 months | IHC | Anti Ki-67 antibody (clone MIB-1) | >10 | 15.33 (4.13–56.96) | <0.001 | |
| Mortality | Wang et al33 | Sweden | 1996 | 21 | 53 | 10.5 years | IHC | Ki-67 | 5 | 0.514 (0.086–3.089) | 0.467 |
| Tisell et al26 | Sweden | 2003 | 36 | 45 | 20 years | IHC | Anti-Ki67 | 1 | 2.12 (0.862–5.233) | 0.102 | |
| Ito et al12 | Japan | 2010 | 371 | 49 | 125 months | IHC | Anti Ki-67 antibody | 3 | 25.64 (2.49–250) | 0.006 | |
| Chen et al20 | USA | 2011 | 9 | 64.8 | 32.5 months | IHC | MIB-1 | 5 | 0.088 (0.008–1.026) | 0.052 | |
| Miyauchi et al22 | Japan | 2013 | 390 | 50.8 | 88 months | IHC | Anti Ki-67 antibody (clone MIB-1) | >10 | 34.08 (3.81–305.16) | 0.002 | |
| Gnemmi et al14 | France | 2014 | 82 | ND | 68 months | IHC | MIB1 | 4 | 6.126 (1.662–22.574) | 0.007 | |
| Jovanovic et al32 | Macedonia | 2015 | 20 | 51.2 | 73 months | IHC | MIB-1 | 6.50 | 24.25 (3.63–161.99) | 0.001 | |
| Feng and Wang62 | China | 2014 | 42 | 53.2 | 7.8 years | IHC | MIB-1 | 1 | 2.28 (0.61–8.55) | 0.228 | |
| DRFS | Gnemmi et al14 | France | 2014 | 82 | ND | 68 months | IHC | MIB-1 | 4 | 7.322 (3.141–17.07) | <0.001 |
Abbreviations: CI, confidence interval; DFS, disease-free survival; DRFS, distant recurrences-free survival; FU, follow-up; HR, hazard ratio; IHC, immunohistochemistry; ND, no data.